Loading News...
Back to Dashboard

Merck & Company, Inc. (MRK)

Real-time intraday values

Market Overview

From:
To:
MRK Intraday
No data available
SymbolMRK
IPO DateJan 2, 1962
CEOMr. Robert M. Davis J.D.
Full Time Employees73k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Performance
PeriodReturn %Value Change
1 Day
+0.67%
+0.89 US$
5 Days
-9.52%
-14.06 US$
1 Month
-10.80%
-16.18 US$
6 Months
+9.22%
+11.29 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of MRK...

Key Statistics
Market Cap
329.65B
P/E Ratio
135.07
Div Yield
2.65%
52W High
$156.92
52W Low
$95.36

Analyst Consensus

ConsensusBuy
Bullish1967.9%
Neutral932.1%
Bearish00.0%

52W Analyst Price Targets

Min Target
$105.00
Max Target
$186.00
Current$133.70
Avg Target$161.53

Analyst Recommendations

Target Price:$161.53($105.00 - $186.00)
FirmRatingTarget PriceUpside PotentialDate
Freedom BrokerHold$140.00+4.71%11/2/2026
Cantor FitzgeraldNeutral$155.00+15.93%11/2/2026
JP MorganOverweight$175.00+30.89%10/30/2026
RBC CapitalSector Perform$140.00+4.71%10/30/2026
GuggenheimBuy$171.00+27.90%10/30/2026
BarclaysOverweight$180.00+34.63%10/26/2026
CitigroupNeutral$145.00+8.45%10/12/2026
RBC CapitalSector Perform$145.00+8.45%10/12/2026
Cantor FitzgeraldNeutral$145.00+8.45%10/8/2026
Morgan StanleyOverweight$177.00+32.39%10/7/2026

Looking for more stocks? Explore them in the screener

Community Thoughts

Share your analysis and sentiment on MRK

Join the community to share your analysis